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1 | Background
Patient-reported outcomes (PRO) provide unique and meaningful insight about 
the effect of a treatment from a patient’s view. Patients with Myeloproliferative 
Neoplasms (MPN) can live with their disease for long periods of time. Therefore 
a comprehensive evaluation of treatment effectiveness should consider the 
patient burden of the disease and treatment effect.
2 | Objective
To evaluate the frequency at which PRO measures are utilized as study endpoints 
and are made publicly available when trial results are published.
3 | Methods
• We searched Citeline® Trialtrove database for randomized clinical trials including 
patients with myeloproliferative neoplasms, initiated between 2006-2016, 
utilizing at least 1 PRO measure.
• We searched PubMed, Medline (Ovid), Google Scholar, ClinicalKey and 
CINAHL databases for publications associated with the trial, and recorded type 
of publication, year, number of randomized patients and reported outcomes.
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4 | Results
• 19 trials (19/30; 63%) included at least one PRO assessment as an endpoint 
(Table 2).
• Among these 19 trials, a variety of PROs were utilized to measure symptoms, 
functional health, and psychological and somatic HRQOL (Figure 2). 
Trial Characteristics n/N %
Total number of MPN studies identified 35 100
Potentially included studies 30
Disease states
Chronic Myelogenous Leukemia (CML) 20/35 57.1
Polycythemia Vera (PV) 2/35 5.7
Primary Myelofibrosis 5/35 14.3
Mastocytosis 2/35 5.7
Essential Thrombocythemia 1/35 2.9
Combination of MPNs 3/35 8.6
Table 1 *Values were rounded to a single decimal point
• Seven studies (36.8%) that included a PRO failed to publish PRO data. 
• 13/19 trials that had a PRO measure (68.4%) were sponsored by industry, three 
(15.8%) by industry-academic and three (15.8%) solely by academic institutions. 
Publication Results n/N %
Included Studies (Studies with ≥1 PRO) 19/30 63.3
PRO as primary endpoint 3/19 15.8
PRO as secondary or exploratory endpoint 16/19 84.2
Studies with published PRO data 12/19 63.2
Comprehensive PRO data published 9/19 47.4
Partial PRO data published 3/19 15.8
PRO data in initial publication 6/12 50
PRO data published >6 months after initial publication 4/12 33.3
Table 2 *Values were rounded to a single decimal point
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5 | Conclusion
• A substantial number of MPN randomized trials did not include a PRO measure. 
• Disease-specific PRO measures were used in 52% of the studies that included a PRO.
• In 37% of trials, PRO data was not reported. 
• Even when reported, PRO data often came late after the initial report and 
partially reported.
6 | Recommendations
The collection of PRO data 
should result in routine, timely 
and appropriate reporting as part 
of the trial outcome publication to 
allow for a thorough assessment of 
investigational drug treatment effects. 
Investigations should focus on 
causal factors that influence the 
underreporting of PRO data 
inclusion in trial publications such 
as: (1) logistics with trial design 
(2) missing data or difficulty with 
data collection in patients with 
advanced or progressive disease 
(3) utilization of disease-specific 
PRO measures
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